water
Why You Don’t Want to Make Death-Star-Sized Drugs
Tuesday, March 2nd, 2010
I was just talking about greasy compounds the other day, and reasons to avoid them. Right on cue, there’s a review article in Expert Opinion in Drug Discovery on lipophilicity
Posted in: In the Pipeline | 0 Comments »
Read the full story
Calorimetry: What Say You?
Monday, March 1st, 2010
I’ve been involved in a mailing list discussion that I wanted to open up to a wider audience in drug discovery, so here goes. We spend our time (well, a lot of it, when we’re not filling out forms) trying to get compound to bind well to our targets
Posted in: In the Pipeline | 0 Comments »
Read the full story
Report: Icahn to launch bid for Genzyme control
Monday, February 22nd, 2010
According to TheStreet ’s source, activist investor Carl Icahn is launching a battle for control of the Genzyme.
Posted in: Pharma News | 0 Comments »
Read the full story
Become a Fan! Shouldn’t FDA Have a Facebook Page?
Wednesday, February 17th, 2010
The FDA has made a clear effort at promoting transparency and engaging consumers more directly with its Transparency Initiative and in putting out requests to get input from the public, such as the recent Part 15 meetings on social media.
Read the full story
Water and Proteins Inside Cells: Sloshing Around, Or Not?
Wednesday, December 9th, 2009
Back in September , talking about the insides of cells, I said: There’s not a lot of bulk water sloshing around in there. It’s all stuck to and sliding around with enzymes, structural proteins, carbohydrates, and the like.
Posted in: In the Pipeline | 0 Comments »
Read the full story
The Bite of the Bivalve – How Much Pressure Can FDA Take?
Wednesday, November 18th, 2009
In the very entertaining, historical and informative book The Big Oyster: History of the Half Shell , Mark Kurlansky outlines the highly central role played by the oyster in the development of America, particularly in the early years of settlement in New York where you could walk down to the water around Manhattan and scoop up a tasty treat with your hand. (Please don't try this today). The book reveals not only what a central role the oyster played in the diet, but in the very economic development of our young country. The numbers of oyster recipes, and the way people wrote about and regarded oysters reveals not only our reliance on them and our high regard for their utility, but a deeply emotional connection as well. The FDA, perhaps, would have been well-advised to read this book before embarking on their recent oyster fiasco. On October 17, FDA's Michael Taylor announced in a speech FDA plans for trying to cut the number of health related issues connected with the consumption of raw oysters , specifically those coming from the Gulf of Mexico. (By way of disclosure, I consume on average about 2 dozen raw oysters a week, and anyone who wants to stop me will have to pry that oyster from my cold, dead hands…) The object of the speech was to signal the FDA's intent to require Gulf oysters to be processed before consumption. In fact, California requires that any Gulf oysters to the state be processed and Michael Taylor notes that as a result, the decline in illness from eating raw oysters dropped considerably. (Though not apparent is whether the drop was due to the fact that the processing worked or that people simply didn't want to buy processed oysters, wishing to stick to the comfort offered by the Kusshi of British Columbia – one of my faves). The reaction was as swift and mighty as the reaction had by an oyster when you try to shuck it. A powerful clamp down by a big muscle. People did not want their oysters to be fooled with and a number of headlines spelled the beginning of a slippery slope for us oyster consumers….
Posted in: Regulatory | 0 Comments »
Read the full story
Google Wave 3 – How Will Google Wave Communications Be Regulated – If At All?
Tuesday, September 8th, 2009
According to Mashable, Google Wave will be released to a limited number of people on September 30, 2009.
Posted in: Regulatory | 0 Comments »
Read the full story
Eloxatin – Sailboat
Tuesday, August 11th, 2009
Deux contextes… Pensez à Eloxatin Métastatique/Adjuvant Schéma FOLFOX4 a démontré Dans le traitement adjuvant du cancer du côlon de stade III (vs le schéma 5-FU/LV): Amélioration de la survie sans maladie
Posted in: Pharma Ads | 0 Comments »
Read the full story
Cruz Roja
Wednesday, July 29th, 2009
Perhaps you can’t see us, but we are there. Cruz Roja
Posted in: Pharma Ads | 0 Comments »
Read the full story
Another Thing We Don’t Know
Tuesday, July 7th, 2009
Hydrogen bonds are important. There, that should be an sweepingly obvious enough statement to get things started. But they really are – hydrogen bonding accounts for the weird properties of water, for one thing, and it’s those weird properties that are keeping us alive.
Posted in: In the Pipeline | 0 Comments »
Read the full story
Business Week – Drug Marketing
Business Week – Pharma Marketing
Cafe Pharma
Clinical Trials.gov
FDA on Twitter
Pharma Live
Pharma Voice